INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Anal Dysplasia Caused by HPV-16/18PRNewsWire • 12/09/20
INOVIO Presents Clinical Results of its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Annual MeetingPRNewsWire • 11/20/20
FDA Lifts Partial Clinical Hold On Inovio's Phase 2 Investigational Coronavirus Vaccine StudyBenzinga • 11/16/20